Video

Dr Clifford Goodman Outlines the Pros and Cons of NCCN Guidelines

Over the years, the National Comprehensive Cancer Network Guidelines have become the market leader for clinical guidelines to consult, but with that success comes responsibility and scrutiny, according to Clifford Goodman, PhD.

Over the years, the National Comprehensive Cancer Network (NCCN) Guidelines have become the market leader for clinical guidelines to consult, but with that success comes responsibility and scrutiny, according to Clifford Goodman, PhD, senior vice president and director at the Center for Comparative Effectiveness Research at The Lewin Group.

NCCN has been successful because it can quickly update its Guidelines and it is easy to access. However, the biggest drawback does not have to do with the content, but how the guidelines are being used.

“Most patients consider they have insufficient information upon which to base decisions at the time they’ve got to make those decisions,” Dr Goodman said.

Related Videos
Picture of San Diego skyline with words ASH Annual Meeting 2024 and health icons overlaid on the bottom
Kara Kelly, MD, chair of pediatrics, Roswell Park Oishei Children's Cancer and Blood Disorders Program
Screenshot of an interview with Amir Ali, PharmD, BCOP
Mansi Shah, MD, assistant professor, Rutgers Cancer Institute of New Jersey
 Alvaro Alencar, MD, associate professor of clinical medicine, chief medical officer, University of Miami Sylvester Comprehensive Cancer Center
Dr Cesar Davila-Chapa
Sandra Cuellar, PharmD
Screenshot of an interview with Nadine Barrett, PhD
Milind Desai, MD
Masanori Aikawa, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo